Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, announced new clinical findings showing that its PromarkerD predictive blood test demonstrates promising prognostic accuracy for diabetic kidney disease (DKD) in Aboriginal people, one of the highest-risk populations for kidney failure globally.
TempraMed Technologies Ltd. (CNSX:VIVI) (FRA:9DY) announced that it has entered into a definitive exclusive distribution agreement with Dolfin Saglik Urunleri ("Dolfin Saglik") to market and sell TempraMed's "VIVI" line of medication temperature-stabilizing products throughout Turkey.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that the US Centers for Medicare & Medicaid Services has published its final determination of the national reimbursement price for the next-generation Promarker(R)D test system, the predictive test for diabetic kidney disease.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that its majority owned subsidiary OxiDx Pty Ltd will today present groundbreaking performance data showing that Thoroughbred horses racing without oxidative stress were 76% more likely to place and 49% more likely to win.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, provided the Chair's Address and Company Presentation to be presented at the Company's Annual General Meeting.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) released a copy of the presentation to be provided by Dr Richard Lipscombe to attendees of the Bell Potter Healthcare Conference, a virtual event being held 18-20 November 2025.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announced that its cash reserves have been further strengthened by the receipt of $2.2 million in research and development tax incentive for the 2024-25 financial year.
